Skip to content
Business Segments · Goodwill

North American Pharmaceutical — Goodwill

McKesson North American Pharmaceutical — Goodwill decreased by 0.7% to $2.78B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.6%, from $2.74B to $2.78B.

Analysis

StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ4 2026May 8, 2026
Rolls up toGoodwill

How to read this metric

A stable or growing balance indicates successful integration and value retention, while a sudden decrease suggests impairment due to poor performance.

Detailed definition

This metric represents the intangible asset value recorded on the balance sheet for the North American Pharmaceutical se...

Peer comparison

Standard balance sheet item for companies that grow through M&A, comparable across all sectors.

Metric ID: mck_segment_north_american_pharmaceutical_goodwill

Historical Data

5 periods
 Q4 '24Q4 '25Q2 '26Q3 '26Q4 '26
Value$2.86B$2.74B$2.78B$2.8B$2.78B
QoQ Change-4.2%+1.6%+0.7%-0.7%
YoY Change-4.2%+1.6%
Range$2.74B$2.86B
CAGR-2.7%
Avg YoY Growth-1.3%
Median YoY Growth-1.3%

Frequently Asked Questions

What is McKesson's north american pharmaceutical — goodwill?
McKesson (MCK) reported north american pharmaceutical — goodwill of $2.78B in Q1 2026.
How has McKesson's north american pharmaceutical — goodwill changed year-over-year?
McKesson's north american pharmaceutical — goodwill increased by 1.6% year-over-year, from $2.74B to $2.78B.
What does north american pharmaceutical — goodwill mean?
The total value of goodwill attributed to the North American Pharmaceutical segment from past acquisitions.